简介:患者女性,15岁。自诉近来学习紧张、精神压力大、睡眠差,时有心前区不适、胸闷、头晕。查体:血压正常,脉搏64次/分左右。心尖搏动不弥散,无震颤,心界不大。心律齐,无病理性杂音。彩色多普勒心脏超声检查示正常。肺部听诊未发现异常。受检前常规心电图正常,未曾服用药物。行3导联24h动态心电图检查,结果示:心率在60~160次/分时,MV5P波直立,P—R间期0.13s,下传的R波呈qRs型,时限正常。当心率46~61次/分时,P—R间期〈0.12s,MV5呈R型,时限0.13s,起始部有δ波。患者出现心前区不适、胸闷、头晕,并随心率的减慢上述症状也随之逐渐加重。在心率逐渐增快时,预激波也随之逐渐消失。
简介:ObjectivesToinvestigatetheeffectsofadrenergicreceptorantagonist(metoprololorprazosin)onmyocardialα1-ARdensityandthechangesofventriculareffectiverefractoryperioddispersion(VERP-D)inrabbitsaftermyocardialinfarction.Methodstwenty-fouradultmaleNewZealandrabbitsweredividedintofourgroupsatrandom:controlgroup(n=6);MIwithplacebogroup(n=6);MIwithmetoprololgroup(n=6);MIwithprazosingroup(n=6).Therabbitsreceivedcorrespondingdrugsforsevendays,beginningatthefirstdayafterMIandmyocardialα1-ARdensityweremeasuredandmeanwhile,myocardialβ-ARwasalsomeasured.ResultsIntheplacebogroup,thedensityofventricularα1-ARwasincreasedincomparisonwithcontrolgroup(α1-ARinnormalregion36.9±0.2vs27.3±0.9fmolmg-1Pro-1,p<0.01;α1-ARinischemicregion33.0±0.9vs26.6±0.4fmolmg-1pro-1P<0.01).Inthemetoprololgroup,itwasalsoincreasedincomparisonwithcontrolgroup(α1-ARinnormalregion44.7±1.5vs27.3±0.9fmolmg-1pro-1,P<0.01;α1-ARinischemicregion33.6±0.5vs26.6±0.4fmolmg-1pro-1,P<0.01).Meanwhilethedensityofventricularα1-ARinnormalregioninthemetoprololgroupwasincreasedincomparisonwithplacebogroup(44.7±1.5vs36.9±0.2fmolmg-1pro-1,P<0.01).Whileitdecreasedintheprazosingroupincomparisonwithcontrolgroup(α1-ARinnormalregion22.5±0.6vs27.3±0.9fmolmg-1pro-1,P<0.01;α1-ARinischemicregion20.9±0.4vs26.6±0.4fmolmg-1pro-1,P<0.01).VERP-DwasincreasedafterMI(P<0.01).Aftertreatmentwithmetoprololorprazosin,VERP-Dwasdecreased(P<0.01).ConclusionsAfteracuteMI,α1-ARofventricularmyocardiumwasupregulated,whichmaybeaccompaniedbyitsactivitation.Thedensityofmyocardialα1-ARbecameupregulatedmoredramaticallytreatedwithmetoprololanddownregulatedwithprazosin.Whentreatedwithmetoprololorprazosin,VERP-Ddecreased.
简介:目的:观察急性心肌梗死(AMI)阿替洛尔或美托洛尔的疗效.方法:选择病情,年龄相匹配的AMI患者随机分为治疗组:阿替洛尔组(n=126)、美托洛尔组(n=122);另设对照组(n=124).观察并对比患者用药1、2、3、4周后血压、心率、室性心律失常、梗死后心绞痛、心功能及心性死亡等情况.结果:治疗组2周后(1)控制最佳心率值(50~65次/min)例数所占的比例明显高于对照组的31.5%(34/124),P<0.05,阿替洛尔组为81.8%(103/126),美托洛尔组为73.0%(89/122);(2)控制最佳血压值(90~100/55~60mmHg)例数的比例明显高于对照组的49.2%(61/124),P<0.05,阿替洛尔组为73.8%(93/126),美托洛尔组为64.0%(78/122);(3)治疗组室性心律失常发生率及梗死后心绞痛例数较对照组明显减少(P<0.05).4周时心功能情况明显好于对照组(P<0.05),治疗组中阿替洛尔组疗效优于美托洛尔组.结论:β1-受体阻滞剂尽早应用于AMI急性期能改善失衡的自主神经功能减少心律失常及梗死后心绞痛的发生及保护心功能,预防心脏突发事件,降低急性期病死率改善远期预后.
简介:患者,女,43岁.1998年11月26日以心慌、胸闷就诊.查体:心率53次/min,心律不齐,心界不大,血压120/90mmHg.因心律失常原因待查,作心电图检查.
简介:ObjectivesToexamineinvivointeractionsbetweenangiotensinⅡ(AngⅡ)AT1areceptor(AT1aR),angiotensin-convertingenzymes(ACE)andACE2usingsmallhairpinRNA(shRNA)gene-silencingmethodsinmicebrainstemnucleustractussolitarius(NTS).MethodsC57BLmice(n=8)wereusedasanimalmodel.MethodofmicroinjectioninthenucleusofNTSwasadopted.Aftertendays,micewerekilledandtheirbraintissuewerefixedandsectioned.TheexpressionlevelsofAT1aR,ACEandACE2mRNAatbothsidesofNTSwereexaminedbyinsituhybridization.Basedoncomparedt-test,thechangingformRNAexpressionwasexamined.ResultsAftertheexpressionofAT1aRmRNAwassignificantlyinhibited(61.6%±6.8%)byAT1aR-shRNA,itwasassociatedwithdecreasesinACE2mRNAexpressionfrom(1.05±0.12)μCi/mgto(0.74±0.09)μCi/mg(29.0%±14.5%,P<0.01)onthesamesideofthebrainstem.ACEmRNAexpressionwasconsistentatbothsides(0.50μCi/mg±0.09μCi/mgand0.53μCi/mg±0.08μCi/mg),withinsignificantdifference(P>0.05).ConclusionsThegenesilencingresultshowedthattherewereinteractionsbetweenbrainstemAT1aRandACE2.ACEmRNAexpressionwasnotalteredbyRNAinterferencetreatmentatAT1aR.
简介:患者男性,56岁,因“心慌、心悸3年,加重伴胸闷5天”入院,患者自3年前始无明显诱因出现心慌,无胸闷憋气,无明显呼吸困难,无胸痛。行Holter检查示:平均心率122次/分,持续性心房扑动(房扑),呈2:1及4:1传导。入院前5天突发胸闷、憋气,出汗,急诊给予“西地兰、速尿”等药物后好转。入院后查体示血压(BP)110/70mmHg(1mmHg=0.133kPa),双肺呼吸音粗,双肺底可及湿罗音,心率116次/分,律不齐,心尖部可闻及2/6级收缩期杂音,查心电图示心房扑动(图1),超声心动示双房增大,二、三尖瓣少量返流,拟诊“扩张型心肌病”,予强心及利尿后症状缓解。